transfusion

Transfusion

Anesthesia (12)
Anticoagulation (7)
Blood count (7)
Chemical analysis (12)
Cure (148)
Detoxification (5)
Diagnosis (514)
Disinfection (11)
Hospitalization (22)
Implant (579)
Injection (225)
Massage (11)
Medical practice (36)
Medical procedure (15)
Medical test (10)
Therapeutics (1600)
Transfusion (19)
Transplant (215)

-like particles could give doctors a new option for curbing surgical bleeding and addressing certain blood clotting disorders without the need for transfusions of natural platelets.

But the researchers believe the particles could also reduce the need for platelet transfusions in patients undergoing chemotherapy or bypass surgery and in those with certain blood disorders.##

##For a patient with insufficient platelets due to bleeding or an inherited disorder physicians often have to resort to platelet transfusions

##These particles could potentially be a way to obviate the need for a transfusion. Though they don t have all the assets of natural platelets a number of intriguing experiments have shown that the particles help augment the clotting process.##

##In addition to providing new treatment options the particles could also cut costs by reducing costly natural transfusions says Lam assistant professor in the biomedical engineering department at Georgia Tech and Emory University.

Six patients, who had been on antiretroviral treatment for around 10 years, each received three transfusions of romidepsin.

--but a transfusion of the wrong blood type can be fatal. For example, the immune system of a type O individual will launch a massive attack on the"invading cells"of a type A individual

#UK plans world's first artificial blood transfusions by 2017 LONDON: The world's first human trial of artificial blood grown in a lab from stem cells is set to take place in the UK by 2017.

and thalassemia who require treatment with regular transfusions and for whom it is difficult to find compatible donors.

This will involve a group of 20 volunteers who will receive a small volume transfusion of between five and ten millilitre of the lab-produced blood."

"Research has laid the foundation for current transfusion and transplantation practices. Continued investment in research and development is critical to our role in saving and improving lives through blood and organ donation,"he added d

have been able to forgo transfusions for at least five months following a gene therapy treatment from bluebird.

theye requiring minimal to no transfusion support. The first patient treated with a previous version of the treatment has now been transfusion-free for over six years

according to bluebird bio President and CEO Nick Leschly, who is also a member of BIO Board of directors.

In other words, the goal is to find an alternative to oxygen-carrying red blood cells that could be used for transfusions.

and his colleagues performed the first small transfusion of such lab-grown red blood cells into human volunteers.

with about 50 per cent still circulating in the blood 26 days after the transfusion.

Douay said in 2011 that it will be a big challenge to scale up the technology to generate enough artificial cells for regular transfusion.

Even then, they produced about a twentieth of the number of cells that would be needed for a single transfusion.